Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar effect on insulin sensitivity in metformin-treated type 2 diabetes
2012-002649-39Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Aleglitazar plus metformin with Placebo plus metformin (2 arms). Primary endpoint: Change in whole-body insulin sensitivity. Started Sep 2012; status: terminated.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002649-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002649-39.